carmengabriela
Did you get Pfizer or Moderna?
That question came up in countless everyday conversations during the past two years as America got vaxxed and de-masked in an attempt to return to a normal life post-lockdown.
So, let’s look at the two
Pandemic Profits In Healthcare
Summary
- Pfizer and Moderna profited by developing vaccines at a breakneck pace, but should investors add them to their portfolios in 2023?
- As the race to develop COVID-19 vaccines became paramount, Moderna’s years of mRNA research would finally pay off.
- Pfizer products have been an integral part of global medicine for decades.
Luckbox magazine, the control freak's guide to life, money and probability, provides entrepreneurs, active investors and risk-takers articles that educate, entertain and serve up actionable advice. It’s a tool that changes the way investors think about the choices they make, looking at investment, business and life decisions through the lens of probability
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.
Business relationship disclosure:This article was written for Luckbox magazine by a contributor.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.